Skip to main content
. Author manuscript; available in PMC: 2018 Aug 12.
Published in final edited form as: Crit Rev Oncog. 2015;20(3-4):199–216. doi: 10.1615/critrevoncog.2015013566

TABLE 2:

Molecular Targets and Potential Inhibitors of Rhabdoid Tumors

Epigenetic
Target		 Mechanism of
Action		 Agent Pediatric Development Comments
EZH2 Histone methylation E7458,
EPZ-6438,
GSK2816126		 Agents pending phase I investigation
DNMT DNA methylation Decitabine,
5-Azacitadine
SGI-110		 Decitabine: phase I single and combination
studies complete
HDAC Histone deacetylation Vorinostat,
Valproic acid,
Romidepsin,
Panobinostat,
Quisinostat,
Others		 Vorinostat: phase I single and combination
studies complete/ongoing
CDK4/cyclinD G1 cell cycle arrest Palbociclib,
LEE011,
P276-00,
LY2835219		 LEE-011: pediatric phase I/II (rhabdoid)
Aurora-A-kinase Antimitotic Alisertib,
TAS-119,
ENMD-2076,
AMG900		 Alisertib: pediatric phase II (rhabdoid)

CDK4, cyclin-dependent kinase 4; DNMT, DNA methyltransferase; EZH2, enhancer of zeste 2 polycomb repressor complex 2; HDAC, histone deacetylase.